𝔖 Bobbio Scriptorium
✦   LIBER   ✦

PA.192 CALCINEURIN INHIBITORS REDUCTION IN LIVER TRANSPLANTED PATIENTS WITH CHRONIC RENAL DYSFUNCTION: RESULTS IN CURRENT CLINICAL PRACTICE

✍ Scribed by F. Gentili; M. Giusto; I. Loria; M. Rossi; P. Berloco; G. Novelli; G. Mennini; S. Ginanni Corradini; A.F. Attili; M. Merli

Book ID
119632867
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
69 KB
Volume
40
Category
Article
ISSN
1590-8658

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Mycophenolate mofetil in combination wit
Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation
✍ Georges-Philippe Pageaux; Lionel Rostaing; Yvon Calmus; Christophe Duvoux; Clair πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 1 views

The purpose of the study was to introduce mycophenolate mofetil (MMF) in liver transplant recipients with renal dysfunction to decrease calcineurin inhibitor (CNI) dosages without increasing rejection risk. In this prospective, multicenter, randomized study, chronic CNI-related renal dysfunction was

Improvement of renal function after the
Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction
✍ Javier F. CastroagudΓ­n; Esther Molina; Rafael Romero; Esteban Otero; Santiago To πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 141 KB πŸ‘ 1 views

Chronic renal dysfunction is a frequent and severe complication in solid-organ transplant recipients. Calcineurin inhibitors (CNIs) are the main pathogenic factors of renal dysfunction. Switching from CNIs to nonnephrotoxic drugs, such as mammalian target of rapamycin inhibitors (everolimus and siro